Povorcitinib showcases substantial total body and facial repigmentation in vitiligo in Phase 2b Trial

Additional endpoints revealed that a greater number of patients in the povorcitinib groups achieved a ≥50% reduction from baseline in both total body and facial depigmentation at Week 52 compared to the initial 24-week findings.

Povorcitinib was well-tolerated at all doses, with treatment-emergent adverse events reported in 89.2% of patients, the most common of which were COVID-19, blood creatine phosphokinase increase, acne, fatigue, and headache.

Importantly, the data indicated that repigmentation was sustained among patients who completed the follow-up period through Week 76, suggesting the durability of the treatment's response.

Vitiligo is a chronic autoimmune disease that results in the depigmentation of the skin. Overactivity of the JAK signaling pathway is believed to play a crucial role in vitiligo's pathogenesis. In the United States alone, more than 1.5 million people are diagnosed with vitiligo, and there is a significant need for effective treatment options.

The 52-week results from this Phase 2b trial offer new hope to individuals with extensive nonsegmental vitiligo. These findings not only represent a significant advance in vitiligo treatment but also exemplify Incyte's commitment to addressing the needs of this patient community.

Source:

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo. Incyte. Date accessed: October 12, 2023.